Clinical Trials

9 enrolled

Phase 2 Not yet recruiting

Hodgkin Disease

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

50 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT03927105 2026-05-07

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

4 enrolled 15 charts

Lymphoma, T-Cell, Peripheral

NCT03057795 2026-05-01

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

62 enrolled 8 charts

Phase EARLY_PHASE1 Active not recruiting

Hodgkin Disease

NCT04134325 2026-04-17

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

10 enrolled

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT06767956 2026-04-13

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Phase 1/2 Withdrawn

Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02681302 2026-04-03

CPIT001

Phase 1/2 Terminated

46 enrolled 13 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT03681561 2026-03-09

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Recruiting

54 enrolled

Phase 1/2 Active not recruiting

Hodgkin Disease

NCT03033914 2026-02-17

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

82 enrolled

Hodgkin Disease

NCT03749018 2026-02-06

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04938232 2026-02-05

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

13 enrolled 19 charts

Hodgkin Disease

NCT04401774 2026-01-27

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Phase 1 Active not recruiting

14 enrolled

CNSLymphoid

Primary Central Nervous System Lymphoma (PCNSL)

NCT03884998 2025-12-30

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

27 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04022980 2025-12-30

Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

14 enrolled

Lymphoma, Neurologic Manifestations

NCT06984146 2025-11-26

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

Phase 2 Recruiting

54 enrolled

Hodgkin Disease

NCT03016871 2025-10-20

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

78 enrolled 15 charts

Phase 1/2 Active not recruiting

Hodgkin Disease

NCT03015896 2025-09-29

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

36 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05788081 2025-08-20

TOP-FLOR

40 enrolled

Lymphoma, Follicular

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Completed

3 enrolled 10 charts

Phase 1 Active not recruiting

Hodgkin Disease

NCT03843294 2025-07-03

Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

18 enrolled

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

BreastDermatologicLymphoid

17 enrolled

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT06931613 2025-04-17

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Phase 2 Enrolling by invitation

20 enrolled

Phase EARLY_PHASE1 Completed

Hodgkin Disease, Recurrence

NCT03311958 2025-04-06

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

15 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

20 enrolled

Hodgkin Disease, Recurrence

NCT04781855 2025-02-28

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Phase 1 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT03366272 2025-01-28

NIVEAU

Phase 2/3 Completed

348 enrolled

Lymphoma, Non-Hodgkin

NCT03712202 2024-11-06

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

155 enrolled

Hodgkin Disease

NCT03586999 2024-10-29

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Phase 1/2 Completed

18 enrolled 14 charts

Lymphoma, T-Cell, Peripheral

NCT04431635 2024-09-27

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

6 enrolled

Indolent Lymphoma

NCT03061188 2024-06-12

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

15 enrolled 18 charts

Lymphoma, T-Cell, Lymphoma, Mantle-Cell

NCT03337919 2024-05-10

ANIMATE

78 enrolled

Hodgkin Disease

NCT03892044 2024-05-02

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

7 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02420912 2024-03-20

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

37 enrolled 12 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03620578 2024-02-14

HO152

97 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03495713 2024-01-17

Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

Phase 2 Terminated

7 enrolled 7 charts

Hodgkin Disease

NCT03229278 2023-12-06

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

DermatologicGenitourinaryHead & NeckLymphoidThoracic

14 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis

NCT03436862 2023-12-05

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

37 enrolled 6 charts

Hodgkin Disease, Hematologic Neoplasms

NCT04091490 2023-09-21

Nivo-DHAP

40 enrolled

Hodgkin Disease

NCT03121677 2023-08-14

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

4 enrolled

Lymphoma, Follicular

NCT04981899 2023-04-12

NICE-40

Phase 1/2 Unknown

30 enrolled

Hodgkin Disease

NCT05772624 2023-03-16

Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

Phase 2 Unknown

16 enrolled

Hodgkin Disease

NCT03305445 2023-02-15

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

6 enrolled